!-- Start Popup -->

DowDuPont (DWDP) to pay $0.38 on Sep 14, 2018; Abeona Therapeutics Inc. (ABEO) Had 5 Analysts Last Week

August 10, 2018 - By Jacqueline McKee

Abeona Therapeutics Inc. (NASDAQ:ABEO) Logo

Among 5 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics had 13 analyst reports since March 20, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, June 5 by H.C. Wainwright. The firm earned “Buy” rating on Thursday, May 3 by H.C. Wainwright. Jefferies maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) on Tuesday, May 22 with “Buy” rating. H.C. Wainwright maintained the shares of ABEO in report on Tuesday, May 29 with “Buy” rating. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) earned “Buy” rating by Cantor Fitzgerald on Tuesday, May 15. The firm earned “Buy” rating on Friday, April 20 by H.C. Wainwright. Cantor Fitzgerald maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) rating on Monday, May 21. Cantor Fitzgerald has “Buy” rating and $3600 target. The company was maintained on Monday, May 14 by H.C. Wainwright. Seaport Global initiated Abeona Therapeutics Inc. (NASDAQ:ABEO) on Tuesday, June 5 with “Buy” rating. As per Tuesday, March 20, the company rating was maintained by Cantor Fitzgerald. See Abeona Therapeutics Inc. (NASDAQ:ABEO) latest ratings:

27/06/2018 Broker: FBR Capital Rating: Buy New Target: $26 Initiates Coverage On
05/06/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain
05/06/2018 Broker: Seaport Global Rating: Buy New Target: $29.0000 Initiate
29/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain
22/05/2018 Broker: Jefferies Rating: Buy New Target: $28.0000 Maintain
21/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $36.0000 Maintain
15/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $36.0000 Maintain
14/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain
03/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain
20/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain

DowDuPont Inc (NYSE:DWDP) is expected to pay $0.38 on Sep 14, 2018. (NYSE:DWDP) shareholders before Aug 30, 2018 will receive the $0.38 dividend. DowDuPont Inc’s current price of $69.02 translates into 0.55% yield. DowDuPont Inc’s dividend has Aug 31, 2018 as record date. Jun 25, 2018 is the announcement. The stock increased 2.01% or $1.36 during the last trading session, reaching $69.02. About 8.10M shares traded or 7.80% up from the average. DowDuPont Inc. (NYSE:DWDP) has 0.00% since August 10, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical DWDP News: 15/03/2018 – DWDP NEGOTIATING MULTI-YEAR PROCUREMENT DEALS TO EXTEND SAVINGS; 15/05/2018 – DowDuPont Presenting at Bank of Montreal Conference Tomorrow; 05/03/2018 – DOWDUPONT SEES INVESTING ANOTHER $6B IN NEW US FACTORIES; 23/05/2018 – EXCLUSIVE-U.S. wants China to approve more biotech crops under trade deal; 22/05/2018 – INSIGHT-Robots fight weeds in challenge to agrochemical giants; 03/05/2018 – DWDP CEO ‘HIGHLY CONFIDENT’ WILL HIT 2018 EARNINGS CONSENSUS; 12/03/2018 – BREAKING: Andrew Liveris to step down as DowDuPont executive chairman next month; Jim Fitterling to be new Dow CEO after planned company break-up – Dow Jones; 02/04/2018 – Fidelity Growth Discovery Adds DowDuPont, Exits J&J; 18/05/2018 – Brian T-DowDuPont bets on canola in race to boost plant proteins; 04/05/2018 – DowDuPont Sees Added Restructuring Charges in 2018, 2019

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $688.29 million. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

More notable recent Abeona Therapeutics Inc. (NASDAQ:ABEO) news were published by: Nasdaq.com which released: “Abeona Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights” on August 09, 2018, also Seekingalpha.com with their article: “Abeona Therapeutics: The Approval Pathway” published on August 02, 2018, Digitaljournal.com published: “NASDAQ: ABEO Shareholder Notice: Investigation over Potential Wrongdoing at Abeona Therapeutics Inc” on July 20, 2018. More interesting news about Abeona Therapeutics Inc. (NASDAQ:ABEO) were released by: Seekingalpha.com and their article: “European Court makes restrictive ruling on genome editing” published on July 30, 2018 as well as Nasdaq.com‘s news article titled: “Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer” with publication date: July 26, 2018.

The stock decreased 1.02% or $0.15 during the last trading session, reaching $14.55. About 423,124 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 191.23% since August 10, 2017 and is uptrending. It has outperformed by 178.66% the S&P500. Some Historical ABEO News: 08/05/2018 – Abeona Therapeutics Announces Upcoming Presentations; 15/03/2018 – ABEO GETS FDA RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202; 14/05/2018 – Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to Its Bd of Directors; 31/05/2018 – Analysis: Positioning to Benefit within Avadel Pharmaceuticals, Abeona Therapeutics, BanColombia S.A, Aercap Holdings N.V, Kite; 23/04/2018 – Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS lllA; 18/05/2018 – ABEONA THERAPEUTICS PROVIDES CLINICAL UPDATE ON MPS lllA GENE THERAPY TRIAL AT THE 21ST ANNUAL ASGCT MEETING; 09/04/2018 – Abeona Therapeutics Closes Above 50-Day Moving Average; 02/04/2018 – Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer; 02/04/2018 – ABEONA THERAPEUTICS INC – THIEL MOST RECENTLY SERVED AS EXECUTIVE VICE PRESIDENT AND CHIEF COMMERCIAL OFFICER OF ALEXION PHARMACEUTICALS, INC; 23/04/2018 – ABEONA THERAPEUTICS INC – COMPANY CONTINUES TO ENGAGE FDA ON ITS ONGOING PHASE 1/2 TRIAL

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts